Equities
Take Action
Take Action
Add this security to watchlist, portfolio, or create an alert to track market movement

Profile data is unavailable for this security.

About the company

AstraZeneca PLC is a patient-focused pharmaceutical company. The Company focuses on discovery and development, manufacturing and commercialization of prescription medicines. The Company is focused on various therapy areas, such as Oncology; BioPharmaceuticals (comprising Cardiovascular, Renal & Metabolism (CVRM) and Respiratory & Immunology (R&I)), and Rare Disease. Its pipeline forms a robust portfolio of investigational therapies in various stages of clinical development. Its pipeline includes the Alexion Rare Disease portfolio and comprises approximately 177 projects, of which 161 are in the clinical phase of development. Its key marketed oncology products include Tagrisso (osimertinib), Lynparza (olaparib), Imfinzi (durvalumab), Koselugo (selumetinib), Farxiga/ Forxiga (dapagliflozin), Roxadustat, Onglyza (saxagliptin) and others. The Company’s geographical segments include United Kingdom, Rest of Europe, The Americas and Asia, Africa & Australasia.

  • Revenue in USD (TTM)45.15bn
  • Net income in USD2.04bn
  • Incorporated1992
  • Employees83.10k
More ▼

Mergers & acquisitions

Acquired companyDeal statusDateDate /
Deal status
AZN:LSE since
announced
Transaction
value
Neogene TherapeuticsAnnounced30 Nov 202230 Nov 2022Announced1.81%--
TeneoTwo IncDeal completed05 Jul 202205 Jul 2022Deal completed4.18%1.27bn
Data delayed at least 20 minutes, as of Dec 05 2022 17:05 GMT.

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
Revenue
(YOY change %)
Revenue
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
Dividend
(5 yr growth rate)
Gilead Sciences, Inc.27.14bn3.33bn111.67bn14.40k33.675.3020.614.122.642.6421.5216.810.41864.396.081,884,445.005.108.356.0710.0274.6279.5612.1922.221.165.860.54558.7610.60-2.124,960.98-14.34-4.999.07
Amgen, Inc.26.33bn6.84bn152.34bn24.20k22.8741.7014.955.7912.4812.4848.096.850.40921.435.221,088,017.0010.6211.0713.7413.4075.7879.2925.9630.881.357.700.913849.282.182.47-18.87-5.261.0111.97
Bristol-Myers Squibb Co46.74bn6.68bn172.50bn32.20k26.455.2710.133.693.073.0721.5315.380.44714.655.721,451,491.006.402.677.943.2978.9174.1814.326.541.314.490.5443163.849.0919.01177.589.43-4.355.22
AstraZeneca plc (ADR)45.15bn2.04bn212.82bn83.10k104.846.0425.844.710.65310.653114.5011.340.44841.205.13543,369.402.032.622.683.6679.2578.904.536.610.60956.440.4546196.2640.5810.22-96.50-49.76-1.01--
Merck & Co Inc58.97bn15.32bn279.00bn68.00k18.236.2714.544.736.046.0123.2317.550.5883.066.53867,264.7015.297.6119.9510.1470.8570.9226.0016.061.2210.490.405986.0617.314.12173.1825.7922.487.49
Pfizer Inc.99.68bn30.23bn285.77bn79.00k9.663.088.152.875.275.1917.3716.510.53233.797.131,261,722.0016.156.6221.018.2565.5174.0430.3521.321.3716.560.28375.7295.169.00238.0525.516.285.39
AbbVie Inc57.82bn13.34bn289.43bn50.00k21.8018.1013.335.017.517.5132.549.040.39855.325.771,156,380.009.257.4611.739.4671.1672.0323.2118.110.83138.810.812897.8922.6916.99151.7114.1310.4417.93
Data as of Dec 05 2022. Currency figures normalised to AstraZeneca PLC's reporting currency: US Dollar USD

Institutional shareholders

9.57%Per cent of shares held by top holders
HolderShares% Held
T. Rowe Price Associates, Inc. (Investment Management)as of 30 Sep 202275.39m2.43%
Wellington Management Co. LLPas of 30 Sep 202252.25m1.69%
PRIMECAP Management Co.as of 30 Sep 202245.61m1.47%
Capital Research & Management Co. (International Investors)as of 30 Sep 202240.33m1.30%
Fidelity Management & Research Co. LLCas of 30 Sep 202221.18m0.68%
GQG Partners LLCas of 30 Sep 202218.38m0.59%
Franklin Advisers, Inc.as of 30 Sep 202214.50m0.47%
CIBC Private Wealth Advisors, Inc.as of 30 Sep 202210.81m0.35%
Norges Bank Investment Managementas of 31 Dec 20219.31m0.30%
Fisher Asset Management LLCas of 30 Sep 20228.94m0.29%
More ▼
Data from 31 Dec 2021 - 30 Sep 2022Source: FactSet Research Systems Inc.
An LSEG Business
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.